Oncolytics Biotech Inc. (ONC.TO)

1.9000 -0.0500 (-2.56%) At close: 03:59PM EST

Oncolytics Biotech Inc.

322 11th Avenue SW
Suite 804
Calgary, AB T2R 0C5
Canada
403 670 7377
https://www.oncolyticsbiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 29

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Matthew C. Coffey M.B.A., Ph.D.	President, CEO & Director	1.05M	N/A	N/A
Mr. Kirk J. Look C.A., CA	Chief Financial Officer	740.85k	N/A	N/A
Mr. Andrew R. de Guttadauro	Global Head of Business Development & President of Oncolytics Biotech (U.S.) Inc	634.74k	N/A	1967
Dr. Thomas C. Heineman M.D., Ph.D.	Chief Medical Officer	872.68k	N/A	N/A
Ms. Allison Hagerman P.Eng., P.M.P.	Vice President of Product Development	582.15k	N/A	N/A
Jon Patton	Director of Investor Relations & Communication	N/A	N/A	N/A
Mr. John Mark Lievonen F.C.A., FCA, LLD	Consultant	25.98k	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Corporate Governance

Oncolytics Biotech Inc.’s ISS Governance QualityScore as of December 1, 2023 is 4. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 2; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.